What proportion of patients with heart failure are candidates for sacubitril/valsartan? Differences between guideline recommendations and regulatory labels

Back

ESC Premium Access

What proportion of patients with heart failure are candidates for sacubitril/valsartan? Differences between guideline recommendations and regulatory labels

Session: Poster Session 7 - Chronic heart failure – Treatment

Topic: Pharmacotherapy

Speaker: Doctor P. Pellicori (Glasgow, GB)

Event: ESC Congress 2018

Congress Presentation

About the speaker

Doctor Pierpaolo Pellicori

University of Glasgow, Glasgow (United Kingdom of Great Britain & Northern Ireland)

3 presentations

1 follower

8 more presentations in this session

Hemodynamic evaluation of patients with advanced heart failure receiving ambulatory intermittent cycles of levosimendan as bridge to transplant

Speaker: Doctor I. Hernandez Gonzalez (Valladolid, ES)

Access

Abstract

Cardiorenal protection by subcutaneous cenderitide in experimental heart failure: a novel and safe therapeutic for humans with LVAD support

Speaker: Doctor T. Ichiki (Rochester, US)

Access

Abstract

Identification of patients eligible to start sacubitril valsartan in a stable heart failure population

Speaker: Doctor S. Aktaa (Leeds, GB)

Access

Abstract

Slides

Initiation of sacubitril/valsartan in hospitalized patients with HFrEF after hemodynamic stabilization: baseline characteristics of the TRANSITION study compared with TITRATION and PARADIGM-HF

Speaker: Doctor M. Senni (Bergamo, IT)

Access

Abstract

Slides

Oral donepezil markedly suppresses the progression of cardiovascular remodeling and improves the prognosis in spontaneously hypertensive rats with myocardial infarction

Speaker: Doctor M. Li (Osaka, JP)

Access

Abstract

Access the full session

Poster Session 7 - Chronic heart failure – Treatment

Speakers: Doctor P. Pellicori, Doctor I. Hernandez Gonzalez, Doctor T. Ichiki, Doctor S. Aktaa, Doctor M. Senni...

Access

About the event

ESC Congress 2018

7 November - 29 August 2018

Sessions Presentations

Congress

What proportion of patients with heart failure are candidates for sacubitril/valsartan? Differences between guideline recommendations and regulatory labels

About the speaker

Doctor Pierpaolo Pellicori

8 more presentations in this session

Hemodynamic evaluation of patients with advanced heart failure receiving ambulatory intermittent cycles of levosimendan as bridge to transplant

Cardiorenal protection by subcutaneous cenderitide in experimental heart failure: a novel and safe therapeutic for humans with LVAD support

Identification of patients eligible to start sacubitril valsartan in a stable heart failure population

Initiation of sacubitril/valsartan in hospitalized patients with HFrEF after hemodynamic stabilization: baseline characteristics of the TRANSITION study compared with TITRATION and PARADIGM-HF

Oral donepezil markedly suppresses the progression of cardiovascular remodeling and improves the prognosis in spontaneously hypertensive rats with myocardial infarction

Access the full session

Poster Session 7 - Chronic heart failure – Treatment

About the event

ESC Congress 2018

ESC 365 is supported by